Osimertinib

About

Therapy type: Targeted therapy

Therapy strategy: EGFR inhibition

Mappings

NCI Thesaurus: Osimertinib (coding:ncit:C116377)

RxNorm: osimertinib (coding:rxcui:1721560, coding:omop:35605522)

View API

Therapeutic response

Precision oncology relationships for therapeutic response involving this therapy.

Organizations
Biomarkers
Cancer types
Therapies
Organizations Biomarkers Cancer types Therapies
EMA (2) FDA (6) HSE (1) EGFR Exon 19 (Deletion) Non-Small Cell Lung Cancer Osimertinib
EMA (2) FDA (6) HSE (1) EGFR p.L858R Non-Small Cell Lung Cancer Osimertinib
FDA (2) EGFR p.L858R Non-Small Cell Lung Cancer Cisplatin, Osimertinib, Pemetrexed
FDA (2) EGFR p.L858R Non-Small Cell Lung Cancer Carboplatin, Osimertinib, Pemetrexed
FDA (2) EGFR Exon 19 (Deletion) Non-Small Cell Lung Cancer Carboplatin, Osimertinib, Pemetrexed
FDA (2) EGFR Exon 19 (Deletion) Non-Small Cell Lung Cancer Cisplatin, Osimertinib, Pemetrexed
EMA (1) FDA (2) HSE (1) EGFR p.T790M Non-Small Cell Lung Cancer Osimertinib
EMA (1) HSE (1) EGFR activating variants Non-Small Cell Lung Cancer Osimertinib
EMA (1) EGFR Exon 19 (Deletion) Non-Small Cell Lung Cancer Cisplatin, Osimertinib
EMA (1) EGFR Exon 19 (Deletion) Non-Small Cell Lung Cancer Carboplatin, Osimertinib
EMA (1) EGFR p.L858R Non-Small Cell Lung Cancer Cisplatin, Osimertinib
EMA (1) EGFR p.L858R Non-Small Cell Lung Cancer Carboplatin, Osimertinib